James Pray - Penumbra President International
| PEN Stock | USD 240.49 1.29 0.54% |
President
Mr. James Pray is the President, International of Penumbra, Inc. He joined Penumbra in 2005. He has served as President, International, since 2015 and as President from 2005 to 2015. Prior to joining Penumbra, Mr. Pray had over 15 years of experience in the medical device industry, much of that in the neurovascular arena. Prior to joining Penumbra, Mr. Pray worked for Boston Scientific Corporationrationration, including as the Director of Marketing for the neurovascular division from 2000 to 2005. Mr. Pray also worked as a Research and Development Engineer and Engineering Manager for SCIMED Life Systems, a medical device company, from 1990 to 1996 since 2015.
| Age | 56 |
| Tenure | 9 years |
| Address | One Penumbra Place, Alameda, CA, United States, 94502 |
| Phone | 510 748 3200 |
| Web | https://www.penumbrainc.com |
Penumbra Management Efficiency
The company has Return on Asset of 0.0333 % which means that on every $100 spent on assets, it made $0.0333 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0313 %, implying that it generated $0.0313 on every 100 dollars invested. Penumbra's management efficiency ratios could be used to measure how well Penumbra manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to 0.07. Also, Return On Capital Employed is likely to grow to 0.06. At this time, Penumbra's Return On Assets are very stable compared to the past year. As of the 22nd of November 2024, Asset Turnover is likely to grow to 0.88, while Other Assets are likely to drop about 47.4 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Tao Levy | Masimo | 50 | |
| Patrick Beyer | CONMED | 58 | |
| Johonna Pelletier | CONMED | 51 | |
| David Vort | iRhythm Technologies | 58 | |
| Mark Day | iRhythm Technologies | 53 | |
| Stanley III | CONMED | 49 | |
| Joseph Flanagan | Integer Holdings Corp | 61 | |
| Micah Young | Masimo | 45 | |
| Charles Alpuche | Insulet | 64 | |
| Todd Garner | CONMED | 55 | |
| Stanley Peters | CONMED | 45 | |
| Stephanie Bolton | LivaNova PLC | 42 | |
| Carter Houghton | Integer Holdings Corp | 55 | |
| Jim Stephens | Integer Holdings Corp | 50 | |
| Ryan Miller | LivaNova PLC | N/A | |
| Leigh Vosseller | Tandem Diabetes Care | 50 | |
| Jason Garland | Integer Holdings Corp | 50 | |
| Payman Khales | Integer Holdings Corp | 54 | |
| Michael Spears | Insulet | 59 | |
| Terence Berge | CONMED | 54 | |
| Jon Coleman | Masimo | 60 | |
Management Performance
| Return On Equity | 0.0313 | ||||
| Return On Asset | 0.0333 |
Penumbra Leadership Team
Elected by the shareholders, the Penumbra's board of directors comprises two types of representatives: Penumbra inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Penumbra. The board's role is to monitor Penumbra's management team and ensure that shareholders' interests are well served. Penumbra's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Penumbra's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Harpreet Grewal, Independent Director | ||
| Ben Tompkins, Executive Development | ||
| Maggie Yuen, Chief Financial Officer | ||
| Surbhi Sarna, Independent Director | ||
| Jee HamlynHarris, Investor Officer | ||
| Don Kassing, Presiding Independent Director | ||
| Bridget ORourke, Independent Director | ||
| Adam JD, Chairman, CoFounder | ||
| Ben Sorci, Executive Operations | ||
| Adam Elsesser, Chairman of the Board, Chief Executive Officer | ||
| Lambert Shiu, Chief Accounting Officer | ||
| James Pray, President International | ||
| Johanna Roberts, Executive Vice President General Counsel, Secretary | ||
| MD FSIR, Chief Officer | ||
| Shruthi Narayan, Executive Interventional | ||
| Jason Mills, Executive Strategy | ||
| Gita Barry, President Healthcare | ||
| Thomas Wilder, Independent Director | ||
| Arani Bose, Executive Director and Chief Innovator | ||
| Johanna JD, General VP | ||
| Lynn Rothman, Executive Vice President, Chief Business Officer | ||
| Janet Leeds, Lead Independent Director | ||
| Arani MD, CoFounder Director | ||
| Pankaj Tiwari, Executive Officer |
Penumbra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Penumbra a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0313 | ||||
| Return On Asset | 0.0333 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 9.17 B | ||||
| Shares Outstanding | 38.38 M | ||||
| Shares Owned By Insiders | 3.86 % | ||||
| Shares Owned By Institutions | 93.42 % | ||||
| Number Of Shares Shorted | 2.26 M | ||||
| Price To Earning | 191.13 X |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Penumbra. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Penumbra Stock, please use our How to Invest in Penumbra guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Penumbra. If investors know Penumbra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Penumbra listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.261 | Earnings Share 0.87 | Revenue Per Share 30.081 | Quarterly Revenue Growth 0.111 | Return On Assets 0.0333 |
The market value of Penumbra is measured differently than its book value, which is the value of Penumbra that is recorded on the company's balance sheet. Investors also form their own opinion of Penumbra's value that differs from its market value or its book value, called intrinsic value, which is Penumbra's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Penumbra's market value can be influenced by many factors that don't directly affect Penumbra's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Penumbra's value and its price as these two are different measures arrived at by different means. Investors typically determine if Penumbra is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Penumbra's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.